PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430128/ http://dx.doi.org/10.1097/01.HS9.0000974648.23994.7c |
_version_ | 1785090881703903232 |
---|---|
author | Qerama, Shaqir Seraj, Liri Kociaj, Jora Buhaljoti, Lorena |
author_facet | Qerama, Shaqir Seraj, Liri Kociaj, Jora Buhaljoti, Lorena |
author_sort | Qerama, Shaqir |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-10430128 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-104301282023-08-17 PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA Qerama, Shaqir Seraj, Liri Kociaj, Jora Buhaljoti, Lorena Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430128/ http://dx.doi.org/10.1097/01.HS9.0000974648.23994.7c Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
spellingShingle | Publication Only Qerama, Shaqir Seraj, Liri Kociaj, Jora Buhaljoti, Lorena PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA |
title | PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA |
title_full | PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA |
title_fullStr | PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA |
title_full_unstemmed | PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA |
title_short | PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA |
title_sort | pb1958: ibrutinib as third line therapy in cll patients, a 5-year study in albania |
topic | Publication Only |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430128/ http://dx.doi.org/10.1097/01.HS9.0000974648.23994.7c |
work_keys_str_mv | AT qeramashaqir pb1958ibrutinibasthirdlinetherapyincllpatientsa5yearstudyinalbania AT serajliri pb1958ibrutinibasthirdlinetherapyincllpatientsa5yearstudyinalbania AT kociajjora pb1958ibrutinibasthirdlinetherapyincllpatientsa5yearstudyinalbania AT buhaljotilorena pb1958ibrutinibasthirdlinetherapyincllpatientsa5yearstudyinalbania |